Free Trial
NASDAQ:NEXI

NexImmune (NEXI) Stock Price, News & Analysis

NexImmune logo

About NexImmune Stock (NASDAQ:NEXI)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.16
52-Week Range
N/A
Volume
10 shs
Average Volume
11,509 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Remove Ads
Receive NEXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter.

NEXI Stock News Headlines

NexImmune moves forward with wind-down process
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
NEXI Stock Alert: NexImmune Delists From Nasdaq
What Is Going on With NexImmune (NEXI) Stock Today?
See More Headlines

NEXI Stock Analysis - Frequently Asked Questions

NexImmune, Inc. (NASDAQ:NEXI) issued its quarterly earnings results on Friday, November, 12th. The company reported ($16.25) earnings per share for the quarter, topping the consensus estimate of ($16.75) by $0.50.

NexImmune's stock reverse split on the morning of Thursday, October 19th 2023. The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

NexImmune (NEXI) raised $75 million in an initial public offering on Friday, February 12th 2021. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. served as the underwriters for the IPO.

Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NexImmune investors own include Athenex (ATNX), Achilles Therapeutics (ACHL), TherapeuticsMD (TXMD), Bolt Biotherapeutics (BOLT), KLX Energy Services (KLXE), Lannett (LCI) and Exela Technologies (XELA).

Company Calendar

Last Earnings
11/12/2021
Today
4/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NEXI
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.32 per share
Price / Book
N/A

Miscellaneous

Free Float
1,187,000
Optionable
Not Optionable
Beta
2.12
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:NEXI) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners